Otolaryngological Progression of Granulomatosis with Polyangiitis after Systemic Treatment with Rituximab

Abstract

While rituximab has been shown to be noninferior to cyclophosphamide with respect to remission from systemic GPA, these patients continue to have chronic otolaryngological manifestations of their disease. Otolaryngologists must continue to play a supportive role throughout their maintenance period.